| IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland P Sansone, G Storci, S Tavolari, T Guarnieri, C Giovannini, M Taffurelli, ... The Journal of clinical investigation 117 (12), 3988-4002, 2007 | 927 | 2007 |
| Cholangiocarcinoma: Epidemiology and risk factors SA Khan, S Tavolari, G Brandi Liver International 39, 19-31, 2019 | 703 | 2019 |
| MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells F Fornari, L Gramantieri, C Giovannini, A Veronese, M Ferracin, ... Cancer research 69 (14), 5761-5767, 2009 | 510 | 2009 |
| Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6–dependent manner AW Studebaker, G Storci, JL Werbeck, P Sansone, AK Sasser, S Tavolari, ... Cancer research 68 (21), 9087-9095, 2008 | 292 | 2008 |
| TNFalpha up‐regulates SLUG via the NF‐kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell‐like phenotype G Storci, P Sansone, S Mari, G D'uva, S Tavolari, T Guarnieri, M Taffurelli, ... Journal of cellular physiology 225 (3), 682-691, 2010 | 205 | 2010 |
| The basal‐like breast carcinoma phenotype is regulated by SLUG gene expression G Storci, P Sansone, D Trere, S Tavolari, M Taffurelli, C Ceccarelli, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2008 | 197 | 2008 |
| Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic … S Tavolari, M Bonafe, M Marini, C Ferreri, G Bartolini, E Brighenti, ... Carcinogenesis 29 (2), 371-380, 2008 | 133 | 2008 |
| Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies G Brandi, A Farioli, A Astolfi, G Biasco, S Tavolari Oncotarget 6 (17), 14744, 2015 | 101 | 2015 |
| Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular carcinoma: where do we stand? A Rizzo, AD Ricci, A Di Federico, G Frega, A Palloni, S Tavolari, G Brandi Frontiers in oncology 11, 803133, 2021 | 97 | 2021 |
| Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives A Rizzo, AD Ricci, S Tavolari, G Brandi Cancer genomics & proteomics 17 (5), 441-452, 2020 | 96 | 2020 |
| Evolution of the experimental models of cholangiocarcinoma A Massa, C Varamo, F Vita, S Tavolari, C Peraldo-Neia, G Brandi, A Rizzo, ... Cancers 12 (8), 2308, 2020 | 95 | 2020 |
| Fibroblast sources: Where can we get them? IR Fernandes, FB Russo, GC Pignatari, MM Evangelinellis, S Tavolari, ... Cytotechnology 68, 223-228, 2016 | 95 | 2016 |
| Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: a systematic review and meta-analysis A Rizzo, G Frega, AD Ricci, A Palloni, F Abbati, S De Lorenzo, M Deserti, ... In vivo 34 (2), 479-488, 2020 | 79 | 2020 |
| Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience G Brandi, A Rizzo, FG Dall’Olio, C Felicani, G Ercolani, M Cescon, ... International Journal of Hyperthermia 37 (1), 479-485, 2020 | 75 | 2020 |
| Second-line treatment in advanced biliary tract cancer: today and tomorrow A Rizzo, AD Ricci, N Tober, MC Nigro, M Mosca, A Palloni, F Abbati, ... Anticancer research 40 (6), 3013-3030, 2020 | 74 | 2020 |
| Immunotherapy in pancreatic cancer: why do we keep failing? A focus on tumor immune microenvironment, predictive biomarkers and treatment outcomes A Di Federico, M Mosca, R Pagani, R Carloni, G Frega, A De Giglio, ... Cancers 14 (10), 2429, 2022 | 72 | 2022 |
| Immunomodulation by 17β-estradiol in bivalve hemocytes L Canesi, C Ciacci, LC Lorusso, M Betti, T Guarnieri, S Tavolari, G Gallo American Journal of Physiology-Regulatory, Integrative and Comparative …, 2006 | 69 | 2006 |
| Long noncoding RNA SBF2-AS1 is critical for tumorigenesis of early-stage lung adenocarcinoma R Chen, W Xia, S Wang, Y Xu, Z Ma, W Xu, E Zhang, J Wang, T Fang, ... Molecular Therapy-Nucleic Acids 16, 543-553, 2019 | 64 | 2019 |
| How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: an updated systematic review and meta-analysis A Rizzo, AD Ricci, G Frega, A Palloni, S De Lorenzo, F Abbati, V Mollica, ... in vivo 34 (4), 1701-1714, 2020 | 63 | 2020 |
| FGFR-targeted therapeutics: Clinical activity, mechanisms of resistance and new directions M Katoh, Y Loriot, G Brandi, S Tavolari, ZA Wainberg, M Katoh Nature Reviews Clinical Oncology 21 (4), 312-329, 2024 | 52 | 2024 |
